{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:46Z","timestamp":1793225986057,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Checkpoint inhibitor\u2013related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase\u2019s characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: \u22644.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: \u226513.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased (<jats:italic>P<\/jats:italic>&amp;lt;0.05). The main change in radiologic features was the absorption of the lesions, and 3 (3\/11) patients in the chronic phase had persistent traction bronchiectasis. For histologic features, most patients had acute fibrinous pneumonitis in the acute phase (5\/8), and most had organizing pneumonia in the subacute phase (5\/6). Other histologic changes advanced over time, with the lesions entering a state of fibrosis. Moreover, the levels of interleukin-6, interleukin-10 and high-sensitivity C-reactive protein (hsCRP) increased in the acute phase and decreased as CIP progressed (IL-6: 17.9 vs. 9.8 vs. 5.7, P=0.018; IL-10: 4.6 vs 3.0 vs. 2.0, P=0.041; hsCRP: 88.2 vs. 19.4 vs. 14.4, P=0.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.935779","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T14:27:53Z","timestamp":1658932073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor\u2013related pneumonitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chengzhi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianxin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Fiorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Igai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/Programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.002","article-title":"Safety and efficacy of PD-1\/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-Small-Cell lung cancer: A systematic review and meta-analysis","volume":"19","author":"Khunger","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A6179","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: A retrospective multi-site assessment of real-world incidence, risk-factors, and management practices","volume":"201","author":"Atchley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non\u2013small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic impact and risk factors of immune-related pneumonitis in patients with non-Small-Cell lung cancer who received programmed death 1 inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.10.009","article-title":"Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer","volume":"21","author":"Suresh","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1258","article-title":"Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience","volume":"10","author":"Lin","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: Assessment and management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2012.68","article-title":"Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes","volume":"5","author":"Gifford","year":"2012","journal-title":"Mucosal Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor\u2013related pneumonitis. an official American thoracic society research statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2019.8506","article-title":"Steroid side effects","volume":"322","author":"Grennan","year":"2019","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor\u2013related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.20892\/j.issn.2095-3941.2020.0102","article-title":"The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients","volume":"17","author":"Zhai","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0717","article-title":"Anti-PD-1-Induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.4.nhlbi-10","article-title":"Lung inflammation and fibrosis","volume":"157","author":"Ward","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mam.2018.06.003","article-title":"Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications","volume":"65","author":"Weiskirchen","year":"2019","journal-title":"Mol Aspects Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1917001","article-title":"Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report","volume":"60","author":"McCallen","year":"2021","journal-title":"Acta Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302470","article-title":"Blockade of IL-6 trans signaling attenuates pulmonary fibrosis","volume":"193","author":"Le","year":"2014","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022667","article-title":"Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury","volume":"6","author":"Pedroza","year":"2011","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11618","article-title":"Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590494","article-title":"Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.11.010","article-title":"Inflammation and fibrosis","author":"Mack","year":"2018","journal-title":"Matrix Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002024","article-title":"Common infections in patients prescribed systemic glucocorticoids in primary care: A population-based cohort study","volume":"13","author":"Fardet","year":"2016","journal-title":"PloS Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B39","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9111064","article-title":"Effects of pirfenidone and nintedanib on markers of systemic oxidative stress and inflammation in patients with idiopathic pulmonary fibrosis: A preliminary report","volume":"9","author":"Fois","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673877","article-title":"Case report: Nintedanib for pembrolizumab-related pneumonitis in a patient with non-small cell lung cancer","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2021.103.08","article-title":"A case report of checkpoint inhibitor pneumonitis caused by PD-1 antibody-safety and effectiveness of pirfenidone","volume":"24","author":"Yu","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.13921","article-title":"Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report","volume":"12","author":"Miao","year":"2021","journal-title":"Thorac Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2019.08.019","article-title":"An open-label study with pirfenidone on chronic hypersensitivity pneumonitis","volume":"56","author":"Mateos-Toledo","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4180","article-title":"A phase I\/II study of neoadjuvant cisplatin, docetaxel, and nintedanib for resectable non-small cell lung cancer","volume":"26","author":"Cascone","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1824631","DOI":"10.1080\/2162402X.2020.1824631","article-title":"Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01550","article-title":"The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC","volume":"9","author":"Marwitz","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.935779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T14:28:03Z","timestamp":1658932083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.935779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.935779"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.935779","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"article-number":"935779"}}